Direct Answer
Incyte Corporation is a biopharmaceutical company built primarily on Jakafi (ruxolitinib), the world's first approved JAK inhibitor and the standard of care for myelofibrosis, with a growing dermatology franchise through Opzelura and a pipeline targeting hematologic malignancies and inflammatory diseases.
Incyte Corporation (INCY): JAK Inhibitors and Oncology Drugs
Company Snapshot
| Ticker | INCY |
|---|---|
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biotechnology |
| Headquarters | Wilmington, Delaware |
| Founded | 1991 |
| CEO | Herve Hoppenot |
| Revenue (FY2024) | ~$3.9 billion |
| CIK | 0000879169 |
| Index membership | S&P 500 |
What Does Incyte Do?
Incyte Corporation is a biopharmaceutical company focused on discovering and commercializing medicines for hematologic malignancies and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte has built its commercial franchise primarily around Jakafi (ruxolitinib), the world's first approved Janus kinase (JAK) inhibitor.
Jakafi inhibits the JAK1 and JAK2 enzymes that drive abnormal cell proliferation in myeloproliferative neoplasms. In myelofibrosis, ruxolitinib reduces spleen volume, alleviates constitutional symptoms (fever, night sweats, weight loss), and has been shown to extend survival. For polycythemia vera patients intolerant to or inadequately controlled by hydroxyurea, Jakafi provides hematocrit control. In graft-versus-host disease, Jakafi suppresses the immune response driving tissue damage in transplant patients.
Incyte's second commercial product, Opzelura (ruxolitinib cream), extends the ruxolitinib platform into dermatology for atopic dermatitis and vitiligo, two high-prevalence inflammatory skin conditions.
Key Products
- Jakafi (ruxolitinib): Approved for myelofibrosis (2011), polycythemia vera (2014), and graft-versus-host disease (acute 2019, chronic 2021). US net product revenue exceeding $2.5B annually. Standard of care in myelofibrosis with an extensive real-world evidence base built over more than a decade of use.
- Opzelura (ruxolitinib cream 1.5%): Approved for atopic dermatitis in patients 12 and older (2021) and for non-segmental vitiligo (2022). The vitiligo indication was a first-of-kind approval for repigmentation. Revenue ramping from launch.
- Jakavi royalties: Novartis sells ruxolitinib internationally as Jakavi under a collaboration agreement with Incyte receiving royalties. International revenues expand the effective market for the molecule.
Frequently Asked Questions
How does Incyte Corporation make money?
Incyte earns revenue primarily from net product revenues from its marketed drugs and royalties. Jakafi (ruxolitinib) in the US -- used for myelofibrosis, polycythemia vera, and acute/chronic graft-versus-host disease -- is the largest revenue source, generating roughly $2.5B+ annually in US net product revenues. Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo is a growing second product. Incyte also earns royalties from Novartis, which sells ruxolitinib outside the US as Jakavi under a collaboration agreement. A growing pipeline of oncology and inflammatory disease candidates provides additional potential revenue sources.
What is Jakafi and why is it important to Incyte?
Jakafi (ruxolitinib) is a JAK1/JAK2 inhibitor approved for myelofibrosis (a rare bone marrow cancer), polycythemia vera (an overproduction of red blood cells), and both acute and chronic graft-versus-host disease (a complication of stem cell transplantation). Jakafi was the first JAK inhibitor approved anywhere in the world (2011) and remains the standard of care in myelofibrosis. Because myelofibrosis is a chronic condition with limited treatment alternatives, Jakafi generates durable, high-margin recurring revenue. The US market for Jakafi represents Incyte's primary revenue source, with Novartis paying royalties on international Jakavi sales under a long-standing collaboration.
What is Opzelura and how does it expand Incyte's market?
Opzelura is a topical cream formulation of ruxolitinib approved for mild-to-moderate atopic dermatitis (eczema) and for non-segmental vitiligo (the first ever approved treatment to restore skin color in vitiligo). Atopic dermatitis is an extremely common inflammatory skin condition affecting millions of patients, representing a far larger addressable market than myelofibrosis. Vitiligo, while less common, had no prior approved treatment, giving Opzelura a pioneering position. The dermatology market requires a large commercial presence and reimbursement establishment that Incyte has been building since Opzelura's launch, with revenue ramping as adoption grows.
What is Incyte's pipeline strategy?
Incyte's pipeline focuses on oncology (hematologic malignancies, solid tumors) and inflammatory diseases, with a scientific emphasis on JAK/STAT pathway inhibition and related immunology targets. Key pipeline programs include parsaclisib (a PI3K-delta inhibitor for lymphoma), axatilimab (a CSF-1R inhibitor for chronic graft-versus-host disease, developed with Syndax Pharmaceuticals), and various combinations of approved drugs. Incyte has a collaboration with Eli Lilly (baricitinib, another JAK inhibitor, where Incyte receives royalties) and Syndax. The company also operates a research facility in Wilmington, Delaware, where it discovers new molecular entities internally.
What are the main risks for Incyte investors?
Key risks include: concentration in Jakafi, whose revenues face long-term erosion as the drug loses patent exclusivity (US composition-of-matter patent expired 2028, with additional method-of-use protection potentially extending market exclusivity); competitive pressure in myelofibrosis from fedratinib (Bristol-Myers Squibb) and pacritinib (CTI BioPharma/Swedish Orphan Biovitrum); regulatory and clinical risk on pipeline candidates; Opzelura reimbursement and commercial ramp uncertainty in the large but competitive atopic dermatitis market; and the challenge of building a second franchise large enough to replace Jakafi revenues over time.